Galderma Announces Nemolizumab Data Published in the New England Journal of Medicine
2023-10-26 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, October 26, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release regarding the results of a Phase III clinical study (OLYMPIA 2) for prurigo nodularis of nemolizumab published in the New England Journal of Medicine (NEJM). Nemolizumab is a humanized anti-human IL-31 receptor A monoclonal antibody, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in prurigo nodularis patients https://www.galderma.com/news/galderma-phase-iii-data-published-new-england-journal-medicine-full-olympia-2-trial-results
The release as fetched from its publisher. chugai-pharm.co.jp ↗